B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GABRA5

MOLECULAR TARGET

gamma-aminobutyric acid type A receptor subunit alpha5

UniProt: P31644NCBI Gene: 255812 compounds

GABRA5 (gamma-aminobutyric acid type A receptor subunit alpha5) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GABRA5

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1gamma-Aminobutyric Acid3.3728
2Pregnanolone2.208
3Bicuculline1.393
4Apigenin 5,7,4'-trihydroxy-flavone,1.102
5chrysin1.102
6Androsterone1.102
7Ciprofloxacin0.691
8Etiocholanolone0.691
9Etomidate Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or0.691
10Ondansetron0.691
11Picrotoxin0.691
12Triiodothyronine0.691

About GABRA5 as a Drug Target

GABRA5 (gamma-aminobutyric acid type A receptor subunit alpha5) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented GABRA5 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GABRA5 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.